With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...
Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...
Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback